Progress in molecular biology and translational science最新文献_第3页

Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment. 先天性淋巴细胞作为癌症治疗的新型免疫治疗靶点的临床和基础科学方面。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-04-12 DOI: 10.1016/bs.pmbts.2024.03.036

Eric Jou

{"title":"Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment.","authors":"Eric Jou","doi":"10.1016/bs.pmbts.2024.03.036","DOIUrl":"https://doi.org/10.1016/bs.pmbts.2024.03.036","url":null,"abstract":"Immunotherapy has revolutionised cancer treatment over the past decade, demonstrating remarkable efficacy across a broad range of cancer types. However, not all patients or cancer types respond to contemporary clinically-utilised immunotherapeutic strategies, which largely focus on harnessing adaptive immune T cells for cancer treatment. Accordingly, it is increasingly recognised that upstream innate immune pathways, which govern and orchestrate the downstream adaptive immune response, may prove critical in overcoming cancer immunotherapeutic resistance. Innate lymphoid cells (ILCs) are the most recently discovered major innate immune cell population. They have overarching roles in homeostasis and orchestrating protective immunity against pathogens. As innate immune counterparts of adaptive immune T cells, ILCs exert effector functions through the secretion of cytokines and direct cell-to-cell contact, with broad influence on the overall immune response. Importantly, dysregulation of ILC subsets have been associated with a range of diseases, including immunodeficiency disorders, allergy, autoimmunity, and more recently, cancer. ILCs may either promote or inhibit cancer initiation and progression depending on the cancer type and the specific ILC subsets involved. Critically, therapeutic targeting of ILCs and their associated cytokines shows promise against a wide range of cancer types in both preclinical models and early phase oncology clinical trials. This chapter provides a comprehensive overview of the current understanding of ILC subsets and the associated cytokines they produce in cancer pathogenesis, with specific focus on how these innate pathways are, or can be targeted, therapeutically to overcome therapeutic resistance and ultimately improve patient care.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"209 ","pages":"1-60"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142506943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in the polymeric nanoparticulate delivery systems for RNA therapeutics. 用于 RNA 治疗的聚合物纳米颗粒输送系统的进展。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-01-30 DOI: 10.1016/bs.pmbts.2024.01.001

Sristi, Waleed H Almalki, Ritu Karwasra, Garima Gupta, Surender Singh, Ajay Sharma, Amirhossein Sahebkar, Prashant Kesharwani

{"title":"Advances in the polymeric nanoparticulate delivery systems for RNA therapeutics.","authors":"Sristi, Waleed H Almalki, Ritu Karwasra, Garima Gupta, Surender Singh, Ajay Sharma, Amirhossein Sahebkar, Prashant Kesharwani","doi":"10.1016/bs.pmbts.2024.01.001","DOIUrl":"10.1016/bs.pmbts.2024.01.001","url":null,"abstract":"RNA therapeutics have emerged as potential treatments for genetic disorders, infectious diseases, and cancer. RNA delivery to target cells for efficient therapeutic applications remains challenging due to instability and poor uptake. Polymeric nanoparticulate delivery systems offer stability, protection, and controlled release. These systems shield RNA from degradation, enabling efficient uptake and extended circulation. Various polymeric nanoparticle platforms have been explored, including lipid-based nanoparticles, polymeric micelles, dendrimers, and polymer-drug conjugates. This review outlines recent breakthroughs of recent advances, design principles, characterization techniques, and performance evaluation of these delivery systems. It highlights their potential in translating preclinical studies into clinical applications. Additionally, the review discusses the application of polymeric nanoparticles in ophthalmic drug delivery, particularly for medications that dissolve poorly in water, and the progress made in siRNA-based therapies for viral infections, autoimmune diseases, and cancers. SiRNA holds great promise for precision medicine and therapeutic intervention, with the ability to target specific genes and modulate disease-associated pathways. The versatility and potency of siRNA-based drugs offer a broader scope for therapeutic intervention compared to traditional biological drugs. As research in RNA therapeutics continues to advance, these technologies hold tremendous potential to revolutionize the treatment of various diseases and improve patient outcomes.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"204 ","pages":"219-248"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140065804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathways of amyloid fibril formation and protein aggregation. 淀粉样纤维形成和蛋白质聚集的途径。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-04-15 DOI: 10.1016/bs.pmbts.2024.03.010

Elaheh Tavili, Fatemeh Aziziyan, Bahareh Dabirmanesh

引用次数: 0

Protein aggregation: An overview. 蛋白质聚集：概述。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-03-31 DOI: 10.1016/bs.pmbts.2024.03.007

Bahareh Dabirmanesh, Khosro Khajeh, Vladimir N Uversky

{"title":"Protein aggregation: An overview.","authors":"Bahareh Dabirmanesh, Khosro Khajeh, Vladimir N Uversky","doi":"10.1016/bs.pmbts.2024.03.007","DOIUrl":"10.1016/bs.pmbts.2024.03.007","url":null,"abstract":"In order for an ordered protein to perform its specific function, it must have a specific molecular structure. Information about this structure is encoded in the protein's amino acid sequence. The unique functional state is achieved as a result of a specific process, known as protein folding. However, as a result of partial or complete unfolding of the polypeptide chain, proteins may misfold and aggregate, leading to the formation of various aggregated structures, such as like amyloid aggregates with the cross-β structure. A variety of cellular biological processes can be affected by protein aggregates that consume essential factors necessary for maintaining proteostasis, which leads to the proteostasis imbalance and further accumulation of protein aggregates, often resulting in age-related neurodegenerative disease progression and aging. However, in addition to their well-established pathological effects, amyloids also play various physiological roles, and many important biological processes involve such 'functional amyloids'. This chapter represents a brief overview of the protein aggregation phenomenon outlines a timeline provides of some key discoveries in this exciting field.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"206 ","pages":"1-10"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141176246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug repurposing for rare diseases. 针对罕见疾病的药物再利用。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-05-17 DOI: 10.1016/bs.pmbts.2024.03.034

Juveriya Israr, Shabroz Alam, Ajay Kumar

引用次数: 0

Preface. 序言

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 DOI: 10.1016/S1877-1173(24)00207-2

引用次数: 0

The promise, progress, and challenges of in situ immunization agents in cancer immunotherapy. 癌症免疫疗法中原位免疫制剂的前景、进展和挑战。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-05-31 DOI: 10.1016/bs.pmbts.2024.02.004

Matthew J Giacalone

引用次数: 0

Drug repurposing for neurodegenerative diseases. 针对神经退行性疾病的药物再利用。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-05-22 DOI: 10.1016/bs.pmbts.2024.03.035

Halak Shukla, Diana John, Shuvomoy Banerjee, Anand Krishna Tiwari

{"title":"Drug repurposing for neurodegenerative diseases.","authors":"Halak Shukla, Diana John, Shuvomoy Banerjee, Anand Krishna Tiwari","doi":"10.1016/bs.pmbts.2024.03.035","DOIUrl":"https://doi.org/10.1016/bs.pmbts.2024.03.035","url":null,"abstract":"Neurodegenerative diseases (NDDs) are neuronal problems that include the brain and spinal cord and result in loss of sensory and motor dysfunction. Common NDDs include Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS) etc. The occurrence of these diseases increases with age and is one of the challenging problems among elderly people. Though, several scientific research has demonstrated the key pathologies associated with NDDs still the underlying mechanisms and molecular details are not well understood and need to be explored and this poses a lack of effective treatments for NDDs. Several lines of evidence have shown that NDDs have a high prevalence and affect more than a billion individuals globally but still, researchers need to work forward in identifying the best therapeutic target for NDDs. Thus, several researchers are working in the directions to find potential therapeutic targets to alter the disease pathology and treat the diseases. Several steps have been taken to identify the early detection of the disease and drug repurposing for effective treatment of NDDs. Moreover, it is logical that current medications are being evaluated for their efficacy in treating such disorders; therefore, drug repurposing would be an efficient, safe, and cost-effective way in finding out better medication. In the current manuscript we discussed the utilization of drugs that have been repurposed for the treatment of AD, PD, HD, MS, and ALS.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"207 ","pages":"249-319"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug repurposing for cancer. 癌症药物的再利用。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-05-11 DOI: 10.1016/bs.pmbts.2024.03.032

Juni Banerjee, Anand Krishna Tiwari, Shuvomoy Banerjee

{"title":"Drug repurposing for cancer.","authors":"Juni Banerjee, Anand Krishna Tiwari, Shuvomoy Banerjee","doi":"10.1016/bs.pmbts.2024.03.032","DOIUrl":"https://doi.org/10.1016/bs.pmbts.2024.03.032","url":null,"abstract":"In the dynamic landscape of cancer therapeutics, the innovative strategy of drug repurposing emerges as a transformative paradigm, heralding a new era in the fight against malignancies. This book chapter aims to embark on the comprehension of the strategic deployment of approved drugs for repurposing and the meticulous journey of drug repurposing from earlier times to the current era. Moreover, the chapter underscores the multifaceted and complex nature of cancer biology, and the evolving field of cancer drug therapeutics while emphasizing the mandate of drug repurposing to advance cancer therapeutics. Importantly, the narrative explores the latest tools, technologies, and cutting-edge methodologies including high-throughput screening, omics technologies, and artificial intelligence-driven approaches, for shaping and accelerating the pace of drug repurposing to uncover novel cancer therapeutic avenues. The chapter critically assesses the breakthroughs, expanding the repertoire of repurposing drug candidates in cancer, and their major categories. Another focal point of this book chapter is that it addresses the emergence of combination therapies involving repurposed drugs, reflecting a shift towards personalized and synergistic treatment approaches. The expert analysis delves into the intricacies of combinatorial regimens, elucidating their potential to target heterogeneous cancer populations and overcome resistance mechanisms, thereby enhancing treatment efficacy. Therefore, this chapter provides in-depth insights into the potential of repurposing towards bringing the much-needed big leap in the field of cancer therapeutics.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"207 ","pages":"123-150"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Drug repurposing for parasitic protozoan diseases. 针对寄生虫原生动物疾病的药物再利用。

3区生物学

Progress in molecular biology and translational science Pub Date : 2024-01-01 Epub Date: 2024-05-16 DOI: 10.1016/bs.pmbts.2024.05.001

Vijayasurya, Swadha Gupta, Smit Shah, Anju Pappachan

{"title":"Drug repurposing for parasitic protozoan diseases.","authors":"Vijayasurya, Swadha Gupta, Smit Shah, Anju Pappachan","doi":"10.1016/bs.pmbts.2024.05.001","DOIUrl":"https://doi.org/10.1016/bs.pmbts.2024.05.001","url":null,"abstract":"Protozoan parasites are major hazards to human health, society, and the economy, especially in equatorial regions of the globe. Parasitic diseases, including leishmaniasis, malaria, and others, contribute towards majority of morbidity and mortality. Around 1.1 million people die from these diseases annually. The lack of licensed vaccinations worsens the worldwide impact of these diseases, highlighting the importance of safe and effective medications for their prevention and treatment. However, the appearance of drug resistance in parasites continuously affects the availability of medications. The demand for novel drugs motivates global antiparasitic drug discovery research, necessitating the implementation of many innovative ways to maintain a continuous supply of promising molecules. Drug repurposing has come out as a compelling tool for drug development, offering a cost-effective and efficient alternative to standard de novo approaches. A thorough examination of drug repositioning candidates revealed that certain drugs may not benefit significantly from their original indications. Still, they may exhibit more pronounced effects in other disorders. Furthermore, certain medications can produce a synergistic effect, resulting in enhanced therapeutic effectiveness when given together. In this chapter, we outline the approaches employed in drug repurposing (sometimes referred to as drug repositioning), propose novel strategies to overcome these hurdles and fully exploit the promise of drug repurposing. We highlight a few major human protozoan diseases and a range of exemplary drugs repurposed for various protozoan infections, providing excellent outcomes for each disease.","PeriodicalId":21157,"journal":{"name":"Progress in molecular biology and translational science","volume":"207 ","pages":"23-58"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141470520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0